SE7605927L - Seen up to Stella a unique crystalline polymorphic form of flunisolind and its priority over for the treatment of respiratory diseases - Google Patents

Seen up to Stella a unique crystalline polymorphic form of flunisolind and its priority over for the treatment of respiratory diseases

Info

Publication number
SE7605927L
SE7605927L SE7605927A SE7605927A SE7605927L SE 7605927 L SE7605927 L SE 7605927L SE 7605927 A SE7605927 A SE 7605927A SE 7605927 A SE7605927 A SE 7605927A SE 7605927 L SE7605927 L SE 7605927L
Authority
SE
Sweden
Prior art keywords
fluorisolide
polymorphic form
solvent
treatment
alpha
Prior art date
Application number
SE7605927A
Other languages
Swedish (sv)
Other versions
SE421426B (en
Inventor
J H Fried
R E Jones
G T Haringer
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US58130075A priority Critical
Priority to US58130175A priority
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of SE7605927L publication Critical patent/SE7605927L/en
Publication of SE421426B publication Critical patent/SE421426B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • C07J71/0026Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031Oxygen-containing hetero ring cyclic ketals at positions 16, 17

Abstract

1525181 Particular crystalline form of fluorisolide SYNTEX (USA) Inc 26 May 1976 [27 May 1975 (2)] 21936/76 Heading C2U [Also in Division A5] A novel crystalline form of 6α - fluoro - 11#,21- dihydroxy - 16α,17α - isopropylidenedioxypregna - 1,4 - diene - 3,20 - dione(fluorisolide) having a characteristic X-ray diffraction pattern is prepared by contacting a polymorphic form of fluorisolide with an aprotic non-polar liquid, particularly a liquid halogenated alkane, which is not a solvent for fluorisolide, or by dissolving a polymorphic form of fluorisolide in an aprotic non-polar solvent, particularly a halogenated hydrocarbon solvent, and crystallizing the required product from the solvent. The novel form is particularly stable in the presence of aerosol propellants and aerosols containing it have use in the treatment of respiratory diseases (see Heading ASB, which also includes a further aspect of the invention).
SE7605927A 1975-05-27 1976-05-25 Seen up to Stella a unique crystalline polymorphic form of alpha-fluoro-11beta, 21-dihydroxy-16alpha, 17alpha-isopropylendioxi-1,4-diene-3,20-dione SE421426B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US58130075A true 1975-05-27 1975-05-27
US58130175A true 1975-05-27 1975-05-27

Publications (2)

Publication Number Publication Date
SE7605927L true SE7605927L (en) 1976-11-28
SE421426B SE421426B (en) 1981-12-21

Family

ID=27078279

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7605927A SE421426B (en) 1975-05-27 1976-05-25 Seen up to Stella a unique crystalline polymorphic form of alpha-fluoro-11beta, 21-dihydroxy-16alpha, 17alpha-isopropylendioxi-1,4-diene-3,20-dione

Country Status (15)

Country Link
JP (1) JPS6247880B2 (en)
AT (1) AT357702B (en)
AU (1) AU506080B2 (en)
CA (1) CA1075228A (en)
DE (2) DE2661037C2 (en)
ES (1) ES448220A1 (en)
FR (1) FR2361900B1 (en)
GB (1) GB1525181A (en)
HK (1) HK8580A (en)
IL (1) IL49652A (en)
MX (1) MX3864E (en)
MY (1) MY8000275A (en)
NL (1) NL191234C (en)
NZ (1) NZ180946A (en)
SE (1) SE421426B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL189201C (en) * 1979-05-21 1993-02-01 Syntex Corp A process for the preparation of a crystalline form of flunisolide.
EP0039369B1 (en) * 1980-05-02 1983-06-15 Schering Corporation Beclomethasone ester solvates, process for their preparation, and preparation of a formulation
GB2127689B (en) * 1982-10-05 1986-07-09 Sandoz Ltd Calcitonin inhalation compositions
US4782047A (en) * 1986-05-22 1988-11-01 Syntex Pharmaceuticals International Ltd. Aqueous steroid formulations for nasal administration
EP0437451B1 (en) * 1988-10-05 1993-06-09 The Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
US5707634A (en) * 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
DE4003272A1 (en) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg New propellant mixtures and their use in drug preparations
PL186196B1 (en) * 1995-06-27 2003-11-28 Boehringer Ingelheim Kg Novel stable preparations of therapeutic agents for obtaining aerosols without gaseous propellant
DE19653969A1 (en) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg New aqueous pharmaceutical preparation for producing propellant-free aerosols
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
DZ2947A1 (en) 1998-11-25 2004-03-15 Chiesi Farma Spa pressurized meter dose inhaler.
IT1313553B1 (en) * 1999-07-23 2002-09-09 Chiesi Farma Spa Formulations optimized consist of dasomministrare steroids solutions for inhalation.
IT1317846B1 (en) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulations containing an anticholinergic drug for chronic obstructive pulmonary disease trattamentodella.
MXPA02011414A (en) 2000-05-22 2003-06-06 Chiesi Farma Spa Stable pharmaceutical solution formulations for pressurised metered dose inhalers.
PT1273292E (en) 2001-07-02 2004-10-29 Chiesi Farma Spa optimized formulation of tobramycin for aerosolization
JP4632687B2 (en) * 2003-04-25 2011-02-23 ロート製薬株式会社 Nasal drops
JP5238779B2 (en) * 2003-04-25 2013-07-17 ロート製薬株式会社 Nasal drops
EP1595531A1 (en) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
CA2905587A1 (en) * 2013-03-15 2014-09-18 Medicis Pharmaceutical Corporation Topical compositions of flunisolide and methods of treatment
US20140274982A1 (en) * 2013-03-15 2014-09-18 Medicis Pharmaceutical Corporation Topical compositions of flunisolide and methods of treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3126375A (en) * 1964-03-24 Chioacyl
GB933867A (en) * 1958-12-08 1963-08-14 American Cyanamid Co Fluorinated steroids
US3282791A (en) * 1965-08-17 1966-11-01 Merck & Co Inc Inhalation aerosol suspension of anhydrous disodium dexamethasone phosphate, propellents, and sorbitan trioleate
US3592930A (en) * 1968-07-19 1971-07-13 Syntex Corp Moisture-deterioratable topical medicaments,particularly anti-inflammatory steroids,in a substantially non-aqueous fatty alcohol-propylene glycol vehicle
DE2015300A1 (en) * 1969-04-01 1970-10-29
GB1429184A (en) * 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
DE2332663C2 (en) * 1973-06-23 1986-07-31 Schering Ag, 1000 Berlin Und 4709 Bergkamen, De
US3934013A (en) * 1975-02-21 1976-01-20 Syntex (U.S.A.) Inc. Pharmaceutical composition

Also Published As

Publication number Publication date
CA1075228A (en) 1980-04-08
NL191234B (en) 1994-11-01
AU1430176A (en) 1977-12-01
SE421426B (en) 1981-12-21
FR2361900B1 (en) 1979-04-13
DE2624924A1 (en) 1977-12-15
NL191234C (en) 1995-04-03
MX3864E (en) 1981-08-26
NZ180946A (en) 1978-07-28
HK8580A (en) 1980-03-14
DE2624924C2 (en) 1986-11-27
DE2661037C2 (en) 1989-04-06
NL7605699A (en) 1976-11-30
MY8000275A (en) 1980-12-31
FR2361900A1 (en) 1978-03-17
ATA388376A (en) 1979-12-15
JPS51144719A (en) 1976-12-13
CA1075228A1 (en)
GB1525181A (en) 1978-09-20
AT357702B (en) 1980-07-25
ES448220A1 (en) 1977-11-01
IL49652A (en) 1979-05-31
JPS6247880B2 (en) 1987-10-09
AU506080B2 (en) 1979-12-13
IL49652D0 (en) 1976-07-30

Similar Documents

Publication Publication Date Title
DE1795451A1 (en) A process for the preparation of novel polyisocyanate compounds and of Formkoerpern
DE1495921A1 (en) A process for the preparation of organosilicon compositions by addition reaction
DE1454862B2 (en) tetrafluoraethylenpolymeren process for the preparation of charge-balancing schla diseases or tubes from
US4156091A (en) 11-Deoxy-11-hydroxymethyl-6-hydroxy-PGE1 compounds
SE443700B (en) Process for the production tell up of a bactericidal organic iodophor
NL186241C (en) A process for the preparation of sulfur containing organosilicon compounds.
IT1251376B (en) Pregna-1,4-diene-3,20-dione 16,17-acetal 21-esters, process for their preparation, composition and methods for the treatment of inflammatory states
ATA768576A (en) A process for the production of optionally foamed polyurethane plastics
DE2505869B2 (en) A process for the preparation of symmetrical carotenoid
SE424838B (en) Process for the production tell up of foamed thermoplastics, such olefinpolymerisater or olefinblandpolymerisater, elastomers or thermoplastic rubbers, as you fornetbara
DE2627879A1 (en) A process for the preparation of polyurethane compositions
AT357140B (en) Adiabatic process for the production of mono-nitrobenzene
SE446988B (en) Process for the production tell up of premium coke
DD133805A5 (en) A process for the preparation of polyurethane ureas
SE432705B (en) Process for the production tell up of a therapeutic delivery system
SE453192B (en) Novel intermediates anvendbara for forward tell up of oxime derivatives of 3-acetoxymethyl-7-acetamido-aminothiazolyl cephalosporin acid and process for the tell accession of the intermediates
DE2804362A1 (en) A process for the preparation of dispersions
DE2629743A1 (en) A process for the manufacture of a prereduced product
AT267865B (en) A process for the preparation of optionally foamed polyurethanes
DE2657044A1 (en) A process for the manufacture of dimethyl terephthalate from polyesterabfaellen
DE2655197A1 (en) Adiabatic process for the production of aromatic mono-nitro compounds
DE2800254A1 (en) A process for the production of high purity silicon
SE7713341L (en) Seen up to Stella branched and cycloaliphatic esters of androstane and ostranserierna
ATA710976A (en) A process for the preparation of polyurethanes
DE2627719A1 (en) A process for the production of polyurea foams

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 7605927-8

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 7605927-8

Format of ref document f/p: F